|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02329 GLORY HEALTH
Nominal 
0.038 +0.001 (+2.703%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 2,705,332 | 7.942% | 2,506,285 | 3,904,672 | 9,898,401 | 5,768,896 |
| Cost of Sales | (2,149,768) | -15.912% | (2,556,565) | (3,791,155) | (8,651,166) | (4,788,575) |
| Gross Profit | 555,564 | -- | (50,280) | 113,517 | 1,247,235 | 980,321 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (498,940) | -- | 263,500 | 20,059 | 115,699 | 315,038 | |
| Change in FV & Impairment on Others | (59,642) | 0.638% | (59,264) | (88,075) | (112,233) | (40,394) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (69,929) | -3.627% | (72,561) | 42,027 | 166,385 | (5,102) | |
| Profit / (Loss) before Taxation | (1,436,308) | 111.651% | (678,620) | (1,090,344) | 876,867 | 516,721 | |
| Taxation | 20,805 | -75.557% | 85,117 | 95,051 | (532,352) | (383,076) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 175,074 | 492.828% | 29,532 | 82,511 | (116,182) | (34,905) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (1,240,429) | 119.946% | (563,971) | (912,782) | 228,333 | 98,740 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 996,117 | 104.099% | 488,055 | 651,128 | 287,934 | 125,053 |
| Depreciation & Amortisation | 89,651 | -5.909% | 95,281 | 123,027 | 225,239 | 95,397 |
| Directors' Emoluments | 6,978 | 10.481% | 6,316 | 8,783 | 11,644 | 14,496 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Disclaimer | -- | Disclaimer | Disclaimer | Unqualified (Modified Report) | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -28.000 | 115.385% | -13.000 | -21.000 | 5.140 | 2.220 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.115 | 0.136 | 0.978 | 1.111 |
| NBV per share ($) | 2.234 | -- | 2.513 | 2.640 | 2.859 | 2.811 |
| Remarks: | Real time quote last updated: 11/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -1,240,429 |
| %Change | 119.946% |
| EPS / (LPS) | RMB -0.280 |
| NBV Per Share (¥) | RMB 2.234 |